Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: Comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core

Magnetic Resonance in Medicine

Volumn 46, Issue 4, 2001, Pages 795-802

  Kobayashi, Hisataka ^a,c   Kawamoto, Satomi ^b   Saga, Tsuneo ^c   Sato, Noriko ^d   Hiraga, Akira ^e   Ishimori, Takayoshi ^a   Akita, Yukio ^c   Mamede, Marcelo H ^a   Konishi, Junji ^a   Togashi, Kaori ^a   Brechbiel, Martin W ^a  

^a HITACHI LTD   (Japan)

^b Department of Nuclear Medicine and Diagnostic Imaging ^*  (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d Otsu Municipal Hospital   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Contrast media; Dendrimer; Liver; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIA; DENDRIMERS; HYDROPHOBICITY; LIVER; MAGNETIC RESONANCE IMAGING; MAMMALS;

CONTRAST-ENHANCED; DIETHYLENETRIAMINE PENTA-ACETIC ACIDS; HEPATIC VEINS; HYDROPHOBIC MOLECULES; MR CONTRAST AGENTS; MRI CONTRAST AGENTS; POLYAMIDOAMINE DENDRIMERS; POLYPROPYLENIMINE;

GADOLINIUM COMPOUNDS;

2 (4 ISOTHIOCYANATOBENZYL) 6 METHYLDIETHYLENETRIAMINEPENTAACETIC ACID; DENDRIMER; GADOLINIUM; GADOLINIUM 2 (4 ISOTHIOCYANATOBENZYL) 6 METHYLDIETHYLENETRIAMINEPENTAACETIC ACID GD 153; GADOLINIUM POLYPROPYLENEIMINE DIAMINOBUTANE GD 153; METAL ION; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; POLYAMIDOAMINE; POLYPROPYLENEIMINE DIAMINOBUTANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTRAST; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG LIVER LEVEL; DRUG SYNTHESIS; HEPATIC VEIN; HYDROPHOBICITY; IMAGE ANALYSIS; IMAGE QUALITY; LIVER PARENCHYMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN;

EID: 0034794601     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.1259     Document Type: Article

References (30)

1. Starburst dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter
2. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo
3. Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging
4. Functional polymers and dendrimers: Reactivity, molecular architecture, and interfacial energy
5. Starburst dendrimers: Enhanced performance and flexibility for immunoassays
6. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapy
7. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody
8. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity
9. Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents
10. Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body
11. Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates
12. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer
13. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with references to their pharmacokinetic properties
14. Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers employed as macromolecular MR contrast agents
15. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications
16. Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat
17. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system
18. NMR tomography of the liver with the new contrast agent Gd-BOPTA. The results of an in-vivo phase-I test
19. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)-preliminary results of phase II clinical application
20. Multihance clinical pharmacology: Biodistribution and MR enhancement of the liver
21. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis
22. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging
23. Phase II clinical evaluation of Gd-EOBDTPA: Dose, safety aspects, and pulse sequence
24. Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA
25. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores
26. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA
27. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: Preliminary results with dynamic MR imaging
28. Hepatobiliary enhancement with Gd-EOB-DTPA: Comparison of spinecho and STIR imaging for detection of experimental liver metastases
29. Pharmacokinetics of 111In- and 125I-labeled anti-Tac single-chain Fv recombinant immunotoxin
30. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody